Evidence map›Paper›PMID 26062979›Full record

ArticleBMC infectious diseases2015

Dramatic reduction in hepatitis B through school-based immunization without a routine infant program in a low endemicity region.

Teegwendé Valérie Porgo, Vladimir Gilca, Gaston De Serres, Michèle Tremblay, Danuta Skowronski

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Teegwendé Valérie PorgoCentre hospitalier universitaire de Québec, Université Laval, Québec, Canada. teegwende-valerie.porgo.1@ulaval.ca.
Vladimir GilcaUniversité Laval, Institut National de Santé Publique du Québec, 2400 d'Estmauville, Beauport, Québec, Qc, G1E7G9, Canada. vladimir.gilca@ssss.gouv.qc.ca.
Gaston De SerresUniversité Laval, Institut National de Santé Publique du Québec, 2400 d'Estmauville, Beauport, Québec, Qc, G1E7G9, Canada. gaston.deserres@inspq.qc.ca.
Michèle TremblayDirection Régionale de Santé Publique de Montréal, Montréal, Canada. Michele.Tremblay@ssss.gouv.qc.ca.
Danuta SkowronskiBritish Columbia Center for Diseases Control, Vancouver, Canada. Danuta.Skowronski@bccdc.ca.
Université Laval · CABC Centre for Disease Control · CACentre hospitalier universitaire de Québec · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis B (HB) prevention in the low-endemicity province of Quebec Canada, (population: ~8.2 million; birth cohort ~85,000/year), includes two decades of pre-adolescent school-based immunization, as well as catch-up immunization for those born since 1983 and pre-natal maternal HBsAg screening. To estimate the potential added benefit of routine infant HB immunization, notifiable disease reports were analyzed (1990-2013). Clinical and demographic information about cases was retrieved from standard questionnaires used by local public health units to investigate HB cases.

methodsThe Quebec provincial registry of notifiable diseases was used to identify confirmed HB cases reported between 1990 and 2013. Clinical and demographic information on cases was retrieved from the standard questionnaires used by local public health units to investigate reported HB cases.

resultsBetween 1990-2013, acute-HB incidence per 100,000 population decreased by 97 % from 6.5 to 0.2. Compared to 1990, incidence fell from 0.6 to zero since 2010 among children ≤9 years of age (yoa), from 3.2 to zero since 2007 in those 10-19 yoa, and from 15 to zero in 2013 among adults 20-29 yoa, previously the age group of highest incidence (all p < 0.0001). During the same period, the newly-reported chronic HB rate per 100,000 decreased by 66 % from 17.7 to 6.1 (p < 0.0001), with a reduction of 92 % (2.4 to 0.2;p < 0.001) in children ≤9 yoa and 83 % (7.2 to 1.2;p = 0.003) in those 10-19 yoa. The incidence of unspecified HB cases did not decrease significantly overall (5.9 vs. 5.4; p = 0.24), in children ≤ 9 yoa (0.3 vs. 0.2;p = 0.70) or 10-19 yoa (1.6 vs. 1.5;p = 0.45). Overall, 91 % of cases ≤19 yoa were immigrants likely infected before arrival in Canada. Among those ≤9 yoa, there were 9 acute-HB case reports between 2005 and 2013, of whom 8 were not preventable by infant immunization.

conclusionsTwo decades of school-based immunization coupled with prenatal screening achieved striking reduction in disease burden in the low-endemicity province of Quebec, Canada. The oldest cohorts targeted by catch-up campaigns are now beyond the average age at childbirth so that neo-natal transmission and the potential incremental benefit of infant immunization will likely further diminish.

Indexed as

AdolescentAdultCanadaChildChild, PreschoolFemaleHepatitis BHepatitis B, ChronicHepatitis B Surface AntigensHepatitis B VaccinesHumansImmunizationImmunization ProgramsIncidenceInfantMaleHepatitis B Surface AntigensHepatitis B Vaccines

Identifiers

PMID26062979
PMCPMC4464119
OpenAlexW1546450389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.